Surprisingly, cobimetinib-sensitive AML cells also had elevated MDM2 levels with 8 versus 5 ng/μg, indicating that NK AML cells with elevated MDM2 levels may be particularly susceptible to the combined treatment with idasanutlin and cobimetinib. This evidence concerns the gene MDM2 and acute myeloid leukemia.